Randomized trial · people

SS-31: no 12-week benefit, walk gains by 36 weeks open-label

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In Barth syndrome, elamipretide showed no clear benefit over placebo at 12 weeks; the walking and symptom gains seen with longer use come from an uncontrolled extension in a handful of patients.

Kind
Randomized trial
Studied in
People
Number studied
12
Published
2021
Journal
Genet Med

What they tested

The team tested whether daily elamipretide improves walking ability and symptoms in people with Barth syndrome, an inherited disorder in which TAZ gene defects leave cardiolipin, a fat in the inner membrane of mitochondria, abnormal.

How the study was done

A randomized, double-blind, placebo-controlled crossover trial in 12 people with Barth syndrome. Each got 40 mg per day of elamipretide or placebo (a dummy treatment) for 12 weeks, then a 4-week break, then 12 weeks on the other option. Ten then went on to an open-label extension, where everyone knowingly got 40 mg per day of elamipretide, and not all of them reached 36 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In the placebo-controlled crossover part, elamipretide did not meet either main goal: better distance on the 6-minute walk test or a better score on a Barth syndrome symptom scale. By 36 weeks of the open-label extension, 6-minute walk distance had gone up by 95.9 m (p = 0.024) and the symptom score had dropped by 2.1 points (p = 0.031), a change toward fewer symptoms. Knee extensor strength, patients' overall impression of their symptoms, and some cardiac measures also improved significantly.

What it doesn’t show

The gains came only in the open-label extension, which had no placebo group, so they can't be separated from other causes. The trial was very small, and even fewer people stayed on through 36 weeks.

The paper

Reid Thompson et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021.

The compound

More studies on SS-31

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo